Eli Lilly Demand Surge Sends Johnson & Johnson Shares Down 1.41%

JNJ•2026-07-06

Johnson & Johnson shares slid 1.41% on July 6 as Eli Lilly's announcement of overwhelming demand spurred profit-taking across large-cap pharmaceuticals. Pfizer, Merck and AbbVie also dropped between 2.15% and 2.47% during the sector pullback.

1. Sector-wide Decline

Johnson & Johnson shares fell 1.41% on July 6, joining Pfizer, Merck and AbbVie declines of 2.15% to 2.47% as investors took profits in large-cap pharmaceutical names following recent gains.

2. Impact of Eli Lilly's Report

Eli Lilly's statement that its businesses were overwhelmed by demand prompted investors to reassess valuations, triggering selloffs in peer healthcare stocks including Johnson & Johnson.

Eli Lilly Demand Surge Sends Johnson & Johnson Shares Down 1.41%

1. Sector-wide Decline

2. Impact of Eli Lilly's Report

Related News

Western Alliance Bank Finances $33M First Phase of Las Vegas’s Historic Marble Manor Redevelopment

Electra Raises US$2.1M in ATM Sales and Grants 91,954 Deferred Shares

Rivian Director and Foundation File $1.5B Equity Sale Notices, Shares Drop

Sources

3 Healthcare ETFs to Own in a Choppy Stock Market

What Eli Lilly Stock Said When It Had Too Much Business

Investor Rights Firm Probes Taylor Morrison’s $72.50 Berkshire Acquisition Deal

Apple Secures Broadcom AI Chips Through 2031 and Readies $2,500 Foldable iPhone